American Elm is dying from Dutch Elm Disease. This may explain the concentrate shortage many practices and antigen suppliers are experiencing. To help, there are many other elm species that are more or less resistant to this fungal disease and still…
2021 ICARS Rhinosinusitis: What You Need To Know
Those interested can still register and stream a video of the webcast at the link below:
https://www.workcast.com/register?cpak=2535926321003375
The 2021 update of ICAR: Rhinosinusitis has been recently published in the International Forum of Allergy and Rhinology and many are asking “What do we need to know?”
Please join us for a live, interactive Rhinocast June 24 at 8 pm jointly sponsored by AAOA and ARS and produced by Wiley, where we will be featuring key content creators and subject editors moderated by Brent Senior.
Discussions will focus on answering key questions:
- What is new and different in 2021 ICAR:RS from the previous edition?
- How does it differ from other similar documents like EPOS 2020?
- And most importantly
- How should rhinologists use it in daily practice?
We will also discuss new ideas in the treatment of rhinosinusitis and where we stand with regard to the evidence. For example, what is the role of steroids and antibiotics in treatment of CRS with and without NP, and when should we consider biologics?
We will also provide opportunities to have your questions answered through audience chat.
We look forward to seeing you there!
Learning objectives:
- To review the overall design and content of 2021 ICAR: Rhinosinusitis
- To identify key changes in the current document compared to the previous ICARS
- To understand how to use ICAR:RS in daily practice
- To review the latest therapies for CRS and discuss where we stand with the evidence
